• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Rite Aid Integrates NarxCare Analytics Directly into its Pharmacist’s Workflow in 12 States

Share:

October 8, 2019

Rite Aid today announced a partnership with Appriss Health, provider of the most comprehensive analytics platform for opioid stewardship and substance use disorder (SUD) in the U.S., to deploy NarxCare into clinical workflow. Rite Aid has effectively implemented NarxCare in 12 States, including all of its Pennsylvania locations.

NarxCare utilizes, analyzes, and presents information from State Prescription Drug Monitoring Programs (PDMP) to enable pharmacists to more efficiently and effectively identify and manage patients at risk for Controlled Substance Misuse and Abuse. NarxCare equips pharmacists with advanced analytics, tools, technology, and invaluable insights that are presented and accessed directly within Rite Aid’s pharmacy management system. NarxCare also provides machine learning and artificial intelligence-based patient risk analysis in a visually interactive format to support pharmacists’ dispensing decisions and state law compliance.

“NarxCare is another efficient and effective solution to help our pharmacists make responsible dispensing decisions, while mitigating possible controlled substance misuse or abuse,” said Jocelyn Konrad, executive vice president, pharmacy and retail operations, Rite Aid. “The integration of NarxCare and PDMP information into our pharmacist’s workflow empowers them to focus more on building relationships with patients and improving health and wellness across the communities they serve.”

“At Rite Aid, patient safety and compliance are important priorities,” said Rob Cohen, President, Appriss Health. “We applaud Rite Aid’s efforts to rapidly deploy technologies to help reduce potential customer risk by leveraging the state PDMPs, utilizing an advanced analytics platform, and integrating these solutions seamlessly into their pharmacists’ daily workflow.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

While pharmacists have access to PDMP information, it can be difficult to navigate and analyze. With NarxCare in place, pharmacists are able to identify potential problems up front, in real-time, for every customer, every time they consider a controlled substance dispensation. Pharmacists also have the support they need to better engage with their customers and determine the best course of action for them, while fulfilling their corresponding responsibility to ensure all controlled substances are filled for a legitimate medical purpose pursuant to a valid prescription within the scope of the prescriber’s practice.

Date: October 08, 2019

Source: BusinessWire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Study: Adheretech’s Smart Pill Bottle Intervention Improves Adherence Without Major Additional ExpenseStudy: Adheretech’s Smart Pill Bottle Intervention Improves Adherence Without Major Additional Expense
  • Merck KGaA goes hostile in $5.9 billion Versum takeover battleMerck KGaA goes hostile in $5.9 billion Versum takeover battle
  • Enhancing Patient Care With a Touchscreen EMR InterfaceEnhancing Patient Care With a Touchscreen EMR Interface
  • Cigna, Express Scripts extend merger termination dateCigna, Express Scripts extend merger termination date
  • Coastal Physicians Medical Group Joins HealthCare PartnersCoastal Physicians Medical Group Joins HealthCare Partners
  • Boehringer Ingelheim Signs Option to Acquire Immunology Partner, Trutino BiosciencesBoehringer Ingelheim Signs Option to Acquire Immunology Partner, Trutino Biosciences
  • BioNTech Adds Two ADCs in Second Deal in as Many MonthsBioNTech Adds Two ADCs in Second Deal in as Many Months
  • BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovationsBELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications